The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index, and 1 are not checked yet.
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Open accessAbstract
Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, restored RSPO3 expression during HSC deactivation52,53 or by therapeutic interventions might help to regain hepatocyte functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [52]
In the citing paper
“Animal models reinforce the capacity of the injured liver to regress fibrosis and provide important platform for dissecting underlying mechanisms, although it should be noted that fibrosis in mice regresses incredibly rapidly, which may be in part attributed to the short duration of models (weeks to months in mice vs. years to decades in humans) and initiation of fibrosis at relatively young age (”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [262]
In the citing paper
“Fibroblast activation also involves increased activity of key glycolytic enzymes, such as hexokinase 2 and lactate dehydrogenase (LDH)47, which in turn increase cell proliferation47 and collagen synthesis48.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
In the citing paper
“During enhanced glycolysis, increased amounts of pyruvate are converted to acetyl-CoA in the mitochondrial matrix47 before entering the citric acid cycle. This yields intermediate metabolites, such as succinate, which promote fibrosis49.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationBataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075
The role of matrix stiffness in regulating cell behavior†
Wells, R. G. (2008) · Hepatology · doi:10.1002/hep.22193 · Cited by 1,059
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Lee, K. S., Buck, M., Houglum, K., & Chojkier, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118304 · Cited by 539
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses
Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P. A., Modlin, R. L., Liblau, R. S., Gressner, A. M., & Kaufmann, S. H. E. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.011 · Cited by 410
Lee, C. G., Cho, S. J., Kang, M. J., Chapoval, S. P., Lee, P. J., Noble, P. W., Yehualaeshet, T., Lu, B., Flavell, R. A., Milbrandt, J., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040104 · Cited by 369
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Self-citationTurning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Metadata
- Authors
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S. M., Dillmann, W., Glass, C. K., & Brenner, D. A.
- Affiliations
- Department of Medicine,
- Universitätsklinikum Aachen (DE)
- Department of Cellular and Molecular Medicine,
- School of Pharmacy, University of California, San Diego, CA 92093;
- University of Southern California (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-05-07
- Volume
- 109
- Issue
- 24
- Pages
- 9448-9453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3386114
- OpenAlex
- W2075290880
- Cited by
- 805
- References
- 27
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 61 · 2023: 59 · 2022: 53 · 2021: 62 · 2020: 64 · 2019: 52 · 2018: 53 · 2017: 61 · 2016: 64 · 2015: 73 · 2014: 63 · 2013: 42 · 2012: 13
- FWCI
- 38.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041804)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- myofibroblasts, hepatic stellate cells, liver fibrosis, fibrosis regression, apoptosis, anti-apoptotic genes, carbon tetrachloride, alcohol-induced liver injury, fibrogenic gene expression
- MeSH terms
- Animals, Liver Cirrhosis, Phenotype, Tamoxifen, Adoptive Transfer, Collagen Type I, Mice, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. https://app.cochat.ai/papers/10.1073/pnas.1201840109
- The paper
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S. M., Dillmann, W., Glass, C. K., & Brenner, D. A. (2012). Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1201840109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.